JP2024054286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024054286A5 JP2024054286A5 JP2024018466A JP2024018466A JP2024054286A5 JP 2024054286 A5 JP2024054286 A5 JP 2024054286A5 JP 2024018466 A JP2024018466 A JP 2024018466A JP 2024018466 A JP2024018466 A JP 2024018466A JP 2024054286 A5 JP2024054286 A5 JP 2024054286A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr1
- cdr2
- cdr3
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 4
- 108020001756 ligand binding domains Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000004161 Claudin-4 Human genes 0.000 claims 3
- 108090000601 Claudin-4 Proteins 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643040P | 2018-03-14 | 2018-03-14 | |
| US62/643,040 | 2018-03-14 | ||
| US201862657151P | 2018-04-13 | 2018-04-13 | |
| US62/657,151 | 2018-04-13 | ||
| JP2020548722A JP2021518104A (ja) | 2018-03-14 | 2019-03-14 | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 |
| PCT/US2019/022272 WO2019178356A1 (en) | 2018-03-14 | 2019-03-14 | Engineered cells, t cell immune modulating antibodies and methods for using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548722A Division JP2021518104A (ja) | 2018-03-14 | 2019-03-14 | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024054286A JP2024054286A (ja) | 2024-04-16 |
| JP2024054286A5 true JP2024054286A5 (https=) | 2024-07-25 |
Family
ID=67908100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548722A Withdrawn JP2021518104A (ja) | 2018-03-14 | 2019-03-14 | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 |
| JP2024018466A Pending JP2024054286A (ja) | 2018-03-14 | 2024-02-09 | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548722A Withdrawn JP2021518104A (ja) | 2018-03-14 | 2019-03-14 | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12258378B2 (https=) |
| EP (1) | EP3765070A4 (https=) |
| JP (2) | JP2021518104A (https=) |
| AU (2) | AU2019235900B2 (https=) |
| WO (1) | WO2019178356A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020113224A2 (en) | 2018-11-30 | 2020-06-04 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
| AU2020290579B2 (en) | 2019-06-14 | 2026-02-12 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 and methods of use thereof |
| EP4069294A4 (en) * | 2019-12-02 | 2024-07-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| EP4106802A1 (en) * | 2020-02-17 | 2022-12-28 | Miltenyi Biotec B.V. & Co. KG | Method for providing personalized cells with chimeric antigen receptors (car) against tumor microenvironment cells |
| KR20230171465A (ko) | 2021-04-22 | 2023-12-20 | 아스텔라스세이야쿠 가부시키가이샤 | 항cldn4-항cd137 이중특이성 항체 |
| WO2023147776A1 (en) * | 2022-02-07 | 2023-08-10 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for enhanced immunotherapies |
| CN114686592B (zh) * | 2022-05-30 | 2022-09-09 | 广东忠信生物科技有限公司 | 一种多类型靶标联合检测的试剂盒及制备方法、使用方法 |
| KR20250099103A (ko) | 2022-08-15 | 2025-07-01 | 다나-파버 캔서 인스티튜트 인크. | Cldn4에 대한 항체 및 이의 사용 방법 |
| CN118252937B (zh) * | 2024-04-07 | 2024-10-22 | 中山大学 | Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US7750123B2 (en) | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
| WO2006089141A2 (en) | 2005-02-18 | 2006-08-24 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| WO2007065027A2 (en) | 2005-12-02 | 2007-06-07 | Dana Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2009134962A2 (en) * | 2008-04-30 | 2009-11-05 | The Regents Of The University Of California | Claudin-4 binding peptides, compositions and methods of use |
| US9527924B2 (en) | 2010-06-02 | 2016-12-27 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| CA2832389A1 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| US9598496B2 (en) | 2011-05-09 | 2017-03-21 | Perseus Proteomics Inc. | Antibody capable of specifically recognizing transferrin receptor |
| US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| MX367668B (es) | 2013-03-15 | 2019-08-30 | Dana Farber Cancer Inst Inc | Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos. |
| AU2015231164B2 (en) | 2014-03-19 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| EP3134111B1 (en) | 2014-04-25 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
| TWI805109B (zh) * | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| SG11201701529YA (en) * | 2014-08-29 | 2017-03-30 | Sorrento Therapeutics Inc | Antibody therapeutics that bind oprf and oprl |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| JP6795505B2 (ja) | 2014-10-06 | 2020-12-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| BR112017013176A2 (en) * | 2014-12-19 | 2018-05-15 | Dana-Farber Cancer Institute Inc. | chimeric antigen receptors and methods for using them |
| KR102668588B1 (ko) | 2015-04-08 | 2024-05-22 | 다나-파버 캔서 인스티튜트 인크. | 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법 |
| JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| EP3349792A1 (en) * | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
-
2019
- 2019-03-14 AU AU2019235900A patent/AU2019235900B2/en active Active
- 2019-03-14 US US16/980,742 patent/US12258378B2/en active Active
- 2019-03-14 WO PCT/US2019/022272 patent/WO2019178356A1/en not_active Ceased
- 2019-03-14 EP EP19767652.1A patent/EP3765070A4/en active Pending
- 2019-03-14 JP JP2020548722A patent/JP2021518104A/ja not_active Withdrawn
-
2024
- 2024-02-09 JP JP2024018466A patent/JP2024054286A/ja active Pending
-
2025
- 2025-02-10 US US19/049,904 patent/US20250296975A1/en active Pending
-
2026
- 2026-03-11 AU AU2026201842A patent/AU2026201842A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024054286A5 (https=) | ||
| JP2021518104A5 (https=) | ||
| JP4843138B2 (ja) | Ｔ細胞阻害性受容体組成物およびその使用 | |
| KR20230147617A (ko) | 아데노신 수용체에 관한 방법 및 조성물 | |
| US10544217B2 (en) | Anti-PD-1 antibodies | |
| US7563869B2 (en) | Substance specific to human PD-1 | |
| ES2643887T3 (es) | Combinación de anticuerpos anti-KIR y anticuerpos anti-PD-1 para tratar el cáncer | |
| EP3470428A1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| EP1242823B1 (en) | Selecting library members capable of binding to epitopes | |
| IL295381A (en) | bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof | |
| CN115850476B (zh) | 一种cll1抗体及其应用 | |
| US20230058227A1 (en) | Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody | |
| BRPI0812913B1 (pt) | Anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano PD-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos | |
| US11760803B2 (en) | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments | |
| JPWO2020077257A5 (https=) | ||
| Gjetting et al. | Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform | |
| CN112262156A (zh) | 抗her2抗体 | |
| CN116813777A (zh) | Lair-1结合剂及其使用方法 | |
| CN114206919A (zh) | 靶向taci的抗体和嵌合抗原受体 | |
| JPWO2019178356A5 (https=) | ||
| IL303312A (en) | BCMA-targeted CAR-T cell therapy for multiple myeloma | |
| EP3956362A1 (en) | Bioassay for t-cell co-stimulatory proteins containing fc domains | |
| EP3470429A1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| CN120607619A (zh) | 5t4结合剂及其用途 | |
| JPWO2020113224A5 (https=) |